Psyence Biomedical opened at $3.18, in line with its previous close of $3.18. In the last trading session, the stock traded between $3.00 and $3.48. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in Psyence Biomedical is now worth
$ 0.04
Resulting in a loss of
$ 99.96 (99.96%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.10 (-2.99%)
Day High
$3.48
Day Low
$3.00
Day Open
$3.18
Prev Close
$3.18
Volume
62,311
1W Return
-3.44%
1M Return
-35.47%
3M Return
-9.26%
6M Return
-41.46%
1Y Return
-81.51%
Fundamentals
Market Cap ($ Mn)
12
PE Ratio
-
PB Ratio
0.61
PEG Ratio
-
ROE
-
ROCE
-50.42%
EPS (TTM)
-
Investment Returns
1 Week
-3.44%
1 Month
-35.47%
3 Months
-9.26%
6 Months
-41.46%
9 Months
4.22%
Financials
Quarterly
All values in $ Mn
0.0
Sep 22
0.0
Sep 23
0.0
Sep 24
0.0
Sep 25
Updates
21Oct
Psyence Biomedical completes $2.6M investment in PsyLabs subsidiary
Completed additional investment of $2,599,896 in PsyLabs. Milestones achieved include ibogaine regulatory documentation and cGMP agreement with Benuvia. Total planned investment in PsyLabs stands at up to $5 million. Backstop commitment required completion by December 31, 2026.
22 days ago
5Oct
Psyence Biomedical signs manufacturing deal with Benuvia for US ibogaine production
Psyence Biomedical signs Manufacturing Services Agreement with Benuvia. Benuvia operates 83,000-square-foot DEA-registered facility in Texas. Deal supports TIRC’s exclusive U.S. access to pharmaceutical-grade ibogaine. Partnership builds integrated U.S. supply and manufacturing platform.
1mo ago
28Sep
Psyence Biomedical unit signs binding ibogaine license with PsyLabs
TIRC signs binding term sheet with PsyLabs for exclusive U.S. ibogaine license and supply. Definitive agreement required by November 30, 2026, or term sheet lapses. Milestone payments up to US$1.3 million plus royalties and exclusivity fees. Existing $5 million investment commitment includes $2.4 million already committed. PsyLabs retains all rights outside the United States.
1mo ago
19Aug
Psyence BioMed welcomes Trump's ibogaine development push
Psyence BioMed Ltd. responded positively to President Trump's announcement on ibogaine development, citing the submission of a 1994 IND application by the University of Miami. The company emphasized its vertically integrated platform and GMP-compliant manufacturing via PsyLabs as it engages with US stakeholders.
